Retrospective review of delayed adverse events secondary to treatment with a smooth, cohesive 20-mg/mL hyaluronic acid filler in 4500 patients - 19/06/20
, Derek H. Jones, MD b, Jean D. Carruthers, MD c, Alastair Carruthers, MD a, Katie Beleznay, MD a, Naissan Wesley, MD d, Jeanette M. Black, MD b, Sherri Vanderveen, BA e, Ardalan Minokadeh, MD, PhD bAbstract |
Background |
Recent publications have suggested an increased risk of delayed adverse events (DAEs) with a smooth, cohesive 20-mg/mL hyaluronic acid filler, Juvéderm Voluma (HA-V).
Objective |
To examine the occurrence of HA-V DAEs and identify patterns and characteristics.
Methods |
Charts from patients who received HA-V between February 1, 2009, and February 28, 2018 from 2 clinics were analyzed.
Results |
In 4500 patients who received 9324 treatments with HA-V, 44 DAEs were identified, for a combined incidence of 0.98% per patient, 0.47% per treatment, and 0.23% per syringe. Patients with DAEs received a slightly larger cumulative amount of HA-V than those who did not. Delayed swelling and nodule formation were the most common reactions and occurred a median of 4 months after treatment, with an increase in frequency between October and January. About a third were preceded by an identifiable immunologic stimulus. DAEs were transient and resolved without incident.
Limitations |
The retrospective nature made it difficult to capture time to resolution or remember potential triggers.
Conclusion |
In this large, long-term, retrospective review, HA-V DAEs occurred at a rate of 0.98% per patient. Although the exact cause has yet to be elucidated, we hypothesize that an increase in fragmentation during the HA-V degradation process may trigger an inflammatory response after an immunologic trigger.
Le texte complet de cet article est disponible en PDF.Key words : adverse events, aesthetics, cosmetic, delayed, fillers, hyaluronic acid, late-onset, nodules, Voluma
Abbreviations used : AE, DAE, HA, HA-V, HMW, LMW
Plan
| Funding sources: Supported by an unrestricted educational grant for editorial assistance provided by Allergan Inc. |
|
| Conflicts of interest: None disclosed. |
Vol 83 - N° 1
P. 86-95 - juillet 2020 Retour au numéro
Article précédent
- A prospective cohort study of condensed low-dose total skin electron beam therapy for mycosis fungoides: Reduction of disease burden and improvement in quality of life
- Andrew Song, Ashley Gochoco, Tingting Zhan, Joya Sahu, Onder Alpdogan, Pierluigi Porcu, Neda Nikbakht, Wenyin Shi
- Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
- Abby S. Van Voorhees, Linda Stein Gold, Mark Lebwohl, Bruce Strober, Charles Lynde, Stephen Tyring, Ashley Cauthen, Howard Sofen, Zuoshun Zhang, Maria Paris, Yao Wang
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?